¾¨Ó㴫ý

Sunday 22 December 2024
Salisbury Foundation Trust

FOI_6744

Internal Reference Number: FOI_6744

Date Request Received: 18/08/2022 00:00:00

Date Request Replied To: 07/09/2022 00:00:00

This response was sent via: By Email

Request Summary: Medication treatment

Request Category: Companies

 
Question Number 1:
How many patients have been treated (for any condition) in the last 4 months with:

• Benralizumab

• Omalizumab

• Reslizumab

• Mepolizumab
 
Answer To Question 1:
Benralizumab 0
Omalizumab 20
Reslizumab 0
Mepolizumab 0
 
Question Number 2:
Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

• Age 6-11

• Age 12-17

• Age 18 and above
 
Answer To Question 2:
6-11 0
12-17 0
18+ 20
 
Question Number 3:
How many patients have been treated in the last 4 months with Dupilumab for:

• Asthma ONLY

• Chronic rhinosinusitis with nasal polyps ONLY
 
Answer To Question 3:
• Asthma ONLY - 0

• Chronic rhinosinusitis with nasal polyps ONLY - 0
 
Question Number 4:
How many patients have been treated in the last 4 months with Omalizumab for:

• Asthma ONLY

• Chronic rhinosinusitis with nasal polyps ONLY

• Chronic Spontaneous Urticaria ONLY
 
Answer To Question 4:
• Asthma ONLY - 45

• Chronic rhinosinusitis with nasal polyps ONLY – 0

• Chronic Spontaneous Urticaria ONLY – 0
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

¾¨Ó㴫ý, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 ¾¨Ó㴫ý
Trust Values